- Home
- EQ
EQ
Equillium Inc.
as 04-01-2025 4:00pm EST
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | N/A | IPO Year: | 2018 |
| Target Price: | $3.00 | AVG Volume (30 days): | 146.8K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $2.43 | Next Earning Date: | 03-27-2025 |
| Revenue: | $41,095,000 | Revenue Growth: | 13.89% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Equillium Inc. (EQ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Keyes Jason A | EQ | Chief Financial Officer | Jan 23 '25 | Sell | $0.65 | 10,000 | $6,500.00 | 37,720 |
Latest Equillium Inc. News
EQ Breaking Stock News: Dive into EQ Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Equillium Full Year 2024 Earnings: Beats Expectations
MT Newswires
5 days ago
Leerink Partners Downgrades Equillium to Market Perform From Outperform, Adjusts Price Target to $1 From $3
Clinical Trials Arena
5 days ago
Equillium pushes for breakthrough status despite missing primary endpoint
Business Wire
6 days ago
Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights
Business Wire
6 days ago
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
Zacks
18 days ago
Are Medical Stocks Lagging Aveanna Healthcare (AVAH) This Year?
Zacks
a month ago
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now
Zacks
2 months ago
Equillium (EQ) Upgraded to Buy: Here's What You Should Know
Compare EQ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EQ Equillium Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.